🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Med-tech startup Innovodigm raises seed funding round led by IAN Group

EntrackrEntrackr · 24d ago
Med-tech startup Innovodigm raises seed funding round led by IAN Group
Medial

Med-tech startup Innovodigm has raised Rs 5.5 crore in a seed funding round led by the IAN Group. IAN contributed Rs 4.5 crore, with the remaining amount invested by PadUp Ventures. The proceeds will be utilized for process optimization, infrastructure scaling, and team expansion to support third-party preclinical validation and prepare for upcoming clinical trials, Innovodigm said in a press release. Co-founded in 2020 by Jhimli Manna and Ayan Chatterjee, Innovodigm develops micro-array patches for vaccines, offering a transformative alternative to traditional injectable immunizations. Designed to overcome challenges such as cold-chain dependency, medical waste, and needle-stick injuries, the MAP uses thermostabilized vaccines that remain viable for up to 120 days at 40°C, eliminating the need for refrigeration and enabling outreach to remote, underserved areas. Innovodigm says that the MAP platform has garnered notable recognition, including selection as a Top 2 Technology at the Nano Electronics Showcase 2025 by the Ministry of Electronics & IT. The company has signed a Material Transfer Agreement (MTA) with a leading Indian vaccine manufacturer for third-party validation, with clinical trials scheduled to commence next year. “Spinning out from IIT Kharagpur’s Microelectronics and MEMS Lab has been fundamental to our scientific foundation. Our MAP platform reflects India’s ability to lead in affordable, scalable vaccine delivery that serves both national and global public health goals,” said Jhimli Manna, CEO of Innovodigm. With plans to expand across India and other low- and middle-income countries, Innovodigm aims to adapt its patch for various vaccines, including measles, hepatitis, flu, and COVID-19 boosters. The company is also working on building local manufacturing hubs so that patches can be made closer to where they’re needed most.

1

Related News

MiClient raises seed round from IAN Group, others

EntrackrEntrackr · 11m ago
MiClient raises seed round from IAN Group, others
Medial

MiClient, an AI-driven B2B sales enablement platform, has raised Rs 3.9 crore in its seed funding round led by IAN Group with participation from Anicut, GSF, RTAF, and Keiretsu. Vikas Kuthiala and Pratik Mathurkar from IAN led the round. The round follows an initial pre-seed investment in October 2023 from 100x.VC. The proceeds will be used to build a stronger team and expand market presence across more geographies in India. In addition to market expansion, MiClient is developing an AI-based model to create quotations and invoices in seconds, further streamlining the sales process for its users. Led by Swati Sharma, MiClient’s easy-to-use CPQ platform helps sales teams close deals three times faster, with the average deal now closing in just 10 days. Expanding further into India’s industrial hubs, MiClient is executing a feet-on-the-street go-to-market strategy. MiClient is expanding into more industrial hubs across India using a direct sales approach. With over 150 customers and over 1,500 users, the company serves SMEs, particularly in the B2B manufacturing sector, with a user-friendly platform.

Ambulance startup Dial4242 raises Rs 9 Cr in pre-Series A round

EntrackrEntrackr · 3d ago
Ambulance startup Dial4242 raises Rs 9 Cr in pre-Series A round
Medial

Ambulance tech startup Dial4242 has raised Rs 9 crore (around $1.04 million) in its pre-Series A funding round led by IAN Group, with participation from BioAngels, IIM Bangalore’s NSRCEL, and other notable angels. Earlier in September 2023, Dial4242 had raised Rs 1 crore in its seed round led by investors G Vamshi Raju, Starfish Ventures, and a clutch of angel investors based in Hyderabad. The proceeds will be used to scale operations, improve ambulance turnaround time from 12 to under 8 minutes, expand medical centers in underserved areas, strengthen tech infrastructure, and boost leadership hiring. Founded in 2016 by Jeetendra Lalwani, Nilesh Mahambre, and Atin Verma, Dial4242 runs a tech-enabled ambulance network in India, covering over 850 cities. Its platform enables real-time tracking, automated dispatch, and 24x7 emergency coordination. With a tech-first, asset-light model, the startup has partnered with firms like Amazon, Zomato, and Swiggy to provide emergency care access to gig workers. The brand also plans to launch a low-cost membership model offering free ambulance access, deepen hospital partnerships, and further improve emergency response standards. Dial4242 competes with the likes of MeduLance, HelpNow, ESahai, AmbiPalm and Mo Ambulance among others in the ambulance booking segment.

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group

EntrackrEntrackr · 17d ago
Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group
Medial

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group Lamark's proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IAN’s angel investors led the round. The Ahmedabad-based company had previously raised $41.3K in a seed funding round led by VIT-TBI and others. The fresh funds will be utilized to accelerate the development of thermostable insulin and expand the biologics platform for global access, Lamark said in a press release. Founded in 2018 by Vaibhav Bhatia, Lamark Biotech aims to reimagine drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. According to Lamark Biotech, it leverages the R&D base of Venture Center, NCL Innovation, and it is advancing a new class of temperature-resilient biologics that retain potency across extreme conditions—ideal for underserved regions where cold storage infrastructure is limited. With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

Download the medial app to read full posts, comements and news.